REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
06/11/2024 13:45
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF2188La&default-theme=true
RNS Number : 2188L MaxCyte, Inc. 06 November 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, November 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that on 5 November 2024, as per a filing lodged with the
U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive
Director of the Company, exercised options over 47,689 shares of common stock
of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689
new shares of Common Stock were issued pursuant to the Company's existing its
block admission facility and were sold by Stanley Erck at a price range
between $3.610 and $3.755 per Common Stock ("Sale"). The sold shares represent
approximately 8.04% of Stanley Erck's total equity and option holdings in the
Company's stock capital, respectively.
Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common
Stock representing 0.2% of the issued stock capital of the Company. Following
the Exercise, Stanley Erck holds a further 276,501 options over Common Stock
and 21,367 restricted stock units.
The sales and option exercises were effected pursuant to a Rule 10b5-1 trading
plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of
shares acquired from exercise of options that expire on 11 November 2024.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Exercise of Options over common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$0.040 47,689
d) Aggregated information
- Aggregated volume 47,689
- Price $0.040
e) Date of the transaction 1 November 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stanley Erck
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Sale of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
$3.6100 100
$3.6400 100
$3.6450 200
$3.6500 1500
$3.6550 1370
$3.6600 500
$3.6650 290
$3.6700 774
$3.6750 780
$3.6800 550
$3.6850 1150
$3.6900 650
$3.6950 3312
$3.7000 5910
$3.7050 1626
$3.7100 888
$3.7150 1375
$3.7200 5460
$3.7250 330
$3.7300 4667
$3.7350 675
$3.7400 6010
$3.7450 795
$3.7500 7297
$3.7550 1380
d) Aggregated information
- Aggregated volume 47,689
- Price $3.7157
e) Date of the transaction 1 November 2024
f) Place of the transaction US Stock Exchange, Nasdaq
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEADFKELELFFARecent news on MaxCyte
See all newsREG - AIM MaxCyte, Inc. - Cancellation - Maxcyte Inc
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Last Day of Dealings on AIM
AnnouncementREG - FTSE Russell MaxCyte, Inc. - MaxCyte
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Result of Annual General Meeting
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Announcement